MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH) saw a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 119,000 shares, agrowthof53.2% from the July 15th total of 77,700 shares. Currently,0.3% of the company’s shares are short sold. Based on an average trading volume of 80,200 shares, the days-to-cover ratio is presently 1.5 days. Based on an average trading volume of 80,200 shares, the days-to-cover ratio is presently 1.5 days. Currently,0.3% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on MDXH. Craig Hallum initiated coverage on MDxHealth in a report on Thursday, July 17th. They set a “buy” rating and a $8.00 target price for the company. Wall Street Zen upgraded MDxHealth to a “hold” rating in a report on Saturday, May 24th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $7.00.

MDxHealth Price Performance

Shares of MDXH stock opened at $2.93 on Thursday. The business’s fifty day moving average is $2.38 and its 200 day moving average is $1.97. The company has a quick ratio of 1.92, a current ratio of 1.31 and a debt-to-equity ratio of 13.81. The stock has a market cap of $138.56 million, a price-to-earnings ratio of -3.33 and a beta of 1.41. MDxHealth has a twelve month low of $1.35 and a twelve month high of $3.48.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The firm had revenue of $26.60 million during the quarter, compared to the consensus estimate of $26.60 million. MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%. MDxHealth has set its Q2 2025 guidance at -0.150–0.150 EPS. Research analysts expect that MDxHealth will post -1.15 EPS for the current fiscal year.

Hedge Funds Weigh In On MDxHealth

A number of institutional investors have recently added to or reduced their stakes in the company. FreeGulliver LLC bought a new position in MDxHealth during the 2nd quarter valued at approximately $273,000. AWM Investment Company Inc. increased its position in MDxHealth by 10.6% during the 1st quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company’s stock valued at $7,414,000 after buying an additional 499,992 shares in the last quarter. Delta Investment Management LLC increased its position in MDxHealth by 459.1% during the 1st quarter. Delta Investment Management LLC now owns 190,100 shares of the company’s stock valued at $270,000 after buying an additional 156,100 shares in the last quarter. Perkins Capital Management Inc. increased its position in MDxHealth by 20.1% during the 1st quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company’s stock valued at $1,678,000 after buying an additional 198,000 shares in the last quarter. Finally, Castleview Partners LLC bought a new position in MDxHealth during the 1st quarter valued at approximately $48,000.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.